Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

2.3%

1 terminated/withdrawn out of 44 trials

Success Rate

97.1%

+10.6% vs industry average

Late-Stage Pipeline

43%

19 trials in Phase 3/4

Results Transparency

0%

0 of 33 completed trials have results

Key Signals

4 recruiting

Enrollment Performance

Analytics

Phase 3
17(41.5%)
Phase 1
15(36.6%)
Phase 2
7(17.1%)
Phase 4
2(4.9%)
41Total
Phase 3(17)
Phase 1(15)
Phase 2(7)
Phase 4(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (44)

Showing 20 of 44 trials
NCT07454369Phase 1Completed

Comparative Bioavailability Study Between Etoricoxib / Betamethasone Administered Individually or in Combination

Role: lead

NCT07444164Phase 1Completed

Comparative Bioavailability Study Between Ticagrelor and ASA Administered Individually or in Combination.

Role: lead

NCT06863662Phase 3Completed

Efficacy and Safety of Etoricoxib/Tizanidine Versus Etoricoxib for Acute Low Back Pain Associated to Muscle Spasm

Role: lead

NCT07328022Phase 3Completed

Efficacy and Safety of Etoricoxib/Betamethasone Combination in Acute Bursitis, Tendinitis and Synovitis

Role: lead

NCT04841096Phase 3Completed

Oral Combination of Glimepiride/Vildagliptin/Metformin in Patients With T2D and Dual Treatment Failure

Role: lead

NCT06916884Phase 3Recruiting

Confirmatory Study on the Efficacy and Safety of the Fixed-dose Combination of Desloratadine/Betamethasone Versus Desloratadine

Role: lead

NCT06863636Phase 3Recruiting

Efficacy and Safety of Celecoxib/Acetaminophen Versus Celecoxib for Diagnosed Osteoarthritis in Acute Exacerbation

Role: lead

NCT06516094Phase 3Completed

Efficacy and Safety in the Combination of Celecoxib / Pregabalin / Vitamin B for Low Back Chronic Pain

Role: lead

NCT06863701Phase 3Recruiting

Efficacy Anda Safety of Etoricoxib With Betamethasone for the Treatment of Acute Gout Arthritis

Role: lead

NCT04927299Phase 3Completed

Efficacy and Safety of Losartan/Chlorthalidone vs Losartan/Hydrochlorothiazide in Essential Arterial Hypertension

Role: lead

NCT06517823Phase 3Completed

Efficacy and Safety of Etoricoxib/Cyanocobalamin Versus Etoricoxib for Acute Low Back Pain

Role: lead

NCT05389150Phase 1Completed

Non-interaction Study Between Pregabalin and Tramadol, Administered Individually or Combination, in Healthy Subjects

Role: lead

NCT05001555Phase 3Completed

Efficacy and Safety of Dexketoprofen/Vitamin B Vs Dexketoprofen for Post-traumatic Cervical Sprain Grade I-II

Role: lead

NCT06531707Phase 3Recruiting

Efficacy and Safety in the Combination of Ibuprofen / Loratadine Versus Ibuprofen Versus Loratadine

Role: lead

NCT05324059Phase 3Completed

Efficacy and Safety of Pregabalin/Tramadol Combination Versus Pregabalin in Acute Pain of Neuropathic Origin

Role: lead

NCT05533073Phase 1Completed

Comparative Bioavailability Study Between Etoricoxib and Tramadol, Administered Individually or in Combination

Role: lead

NCT05428293Phase 1Completed

Pharmacokinetic Interaction Between Ibuprofen and Acetaminophen Oral Suspension

Role: lead

NCT05428306Phase 1Completed

Pharmacokinetic Interaction Between Ibuprofen and Acetaminophen, Tablets Administered Individually or in Combination

Role: lead

NCT05105139Completed

Study to Evaluate the Safety of Sebryl® and Sebryl Plus® in Seborrheic Dermatitis and Psoriasis of Scalp

Role: lead

NCT04968158Phase 3Completed

Efficacy and Safety of Fixed-dose Combination of Etoricoxib/Tramadol vs Acetaminophen/Tramadol for Acute Low Back Pain

Role: lead